CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Estadual Paulista (UNESP). Campus de Araraquara. Faculdade de Ciências Farmacêuticas (FCFAR) (Institutional affiliation for the last research proposal) Birthplace: Brazil
graduation at Ciências Biológicas Modalidade Médica from Centro Universitário Barão de Mauá (2004), master's at Pharmacy from Universidade Estadual Paulista Júlio de Mesquita Filho (2009) and doctorate at Pharmacy from Universidade Estadual Paulista Júlio de Mesquita Filho (2011). Has experience in Microbiology, acting on the following subjects: mycobacterium tuberculosis, maba, new drugs, anti-m. tuberculosis activity and novos fármacos. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Tuberculosis (TB) is one of the 10 leading causes of death in the world and is the disease caused by a single infectious agent with a higher mortality rate, being ahead of HIV/AIDS. Its complex and long treatment, added to the high rate of bacterial resistance, makes it one of the targets pointed out by the World Health Organization along with 12 more bacteria as determinants in the urgen…
In the last report of the World Health Organization 12 bacteria with high incidence of resistance and more Mycobacterium tuberculosis were determinant in the urgency in research and development (R&D) of new antimicrobials. In 2016 there were 10.4 million new cases of tuberculosis (TB) in the world, of which only 6 million were diagnosed and reported. Resistance to antimicrobials against T…
Mycobacterium tuberculosis (MTB), agent of tuberculosis (TB), is responsible for the death of around 2-3 million people annually and a global economic toll of ~$12 billion each year. For more than 50 years after the introduction of rifampicin (RMP) in 1960, no new drug had been developed against TB. All the need of a new molecule, led to quickly TMC-207 approval by the FDA (Food and Drug …
The development of new molecules is the basis of Pharmaceutical Microbiology, mainly because bacteria rapidly develop resistance to various drugs, including first-line drugs. The use of antimicrobial peptides (AMPs) has been an interesting and current area of research because these molecules are not considered drugs and generally do not generate or generate low resistance. Tuberculosis (T…
Tuberculosis is a public health problem that has been present since the dawn of humanity. Elucidated by Robert Koch, this disease has as its main pathological agent the bacillus of Mycobacterium tuberculosis, which causes an infection in the pulmonary alveoli. It stands out as a pathology for its high rate of resistance to antimicrobials and also for being the main cause of death from a s…
Urinary tract infections are frequent worldwide, with Uropathogenic Escherichia coli (UPEC) being the pathogen responsible for 75% of these cases. In April 2019, the WHO and the UN published an article on the need for the development of new substances capable of combating infections caused by Multi-Drug Resistant bacteria (MDR), placing MDR UPECs on the priority pathogen list. The search …
(Only some records are available in English at this moment)
Tuberculosis (TB) is an infectious disease whose main etiological agent is Mycobacterium tuberculosis. According to the WHO, cases of death from TB exceed the cases of HIV in the world, about 1.3 million a year. This chronic disease is often asymptomatic, coming to manifest itself only many years after the individual has been infected, thus estimating that about 1/4 of the world populatio…
Since tuberculosis (TB) is still a global health issue and, several strategies to improve its treatment have been analyzed. Nanotechnology is one of them. Liposomes are nanostructures that were chosen for this project due to their capacity of encapsulating lipo or hydrophilic drugs and of using biocompatible lipids in their synthesis. Likewise, a moxifloxacin was the drug of choice to be …
Considering the accelerated pace of new cases emergence of tuberculosis (TB), about 10 million per year, the high rates of resistance to main classes of antimicrobials, and taking into account that TB occupies the first place in the ranking of causes of death by an infectious agent, becomes evident the need to control and combat this disease which poses a serious threat to global public h…
(Only some records are available in English at this moment)
The emergence of multidrug-resistant bacteria that are resistant to most known antibiotics has resulted in a global health crisis. Thus, new antimicrobial drugs with new modes of action are urgently needed. Antimicrobial peptides (AMPs) are part of the innate immune defense of all multicellular organisms. Current development of AMPs as potential antibiotics is an interesting area of resea…
Tuberculosis is a contagious disease caused by Mycobacterium tuberculosis, which mainly attacks lungs and other parts of the body such as kidneys, eyes and bones. It is a disease of global incidence, infecting one third of the entire world population. With this, tuberculosis is currently responsible for deaths of 1.7 million people per year; values higher than those observed for any other…
This project is associated to FAPESP doctoral fellowship process number 2014/11586-9, entitled: "Studies in vitro and in vivo of furoxan compounds with potential application for the treatment of tuberculosis". The work will be performed under supervisor of the Prof. Scott Gary Franzblau (Professor and Director) at the University of Illinois at Chicago (Institute for Tuberculosis Research)…
| 1 / 1 | Ongoing research grants |
| 2 / 2 | Completed research grants |
| 4 / 4 | Ongoing scholarships in Brazil |
| 17 / 16 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 2 / 2 | Completed scholarships abroad |
| 27 / 26 | All research grants and scholarships |
| Associated processes | |